WO2001089451A3 - Protease inhibitors - Google Patents

Protease inhibitors Download PDF

Info

Publication number
WO2001089451A3
WO2001089451A3 PCT/US2001/012326 US0112326W WO0189451A3 WO 2001089451 A3 WO2001089451 A3 WO 2001089451A3 US 0112326 W US0112326 W US 0112326W WO 0189451 A3 WO0189451 A3 WO 0189451A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibition
treatment
cathepsin
prevention
protease inhibitors
Prior art date
Application number
PCT/US2001/012326
Other languages
French (fr)
Other versions
WO2001089451A2 (en
Inventor
Maxwell D Cummings
Robert W Marquis Jr
Yu Ru
Scott K Thompson
Daniel F Veber
Dennis S Yamashita
Original Assignee
Smithkline Beecham Corp
Maxwell D Cummings
Robert W Marquis Jr
Yu Ru
Scott K Thompson
Daniel F Veber
Dennis S Yamashita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU90507/01A priority Critical patent/AU9050701A/en
Application filed by Smithkline Beecham Corp, Maxwell D Cummings, Robert W Marquis Jr, Yu Ru, Scott K Thompson, Daniel F Veber, Dennis S Yamashita filed Critical Smithkline Beecham Corp
Priority to IL15108701A priority patent/IL151087A0/en
Priority to CA002406829A priority patent/CA2406829A1/en
Priority to EP01970508A priority patent/EP1278502A4/en
Priority to BRPI0108954-4A priority patent/BR0108954A/en
Priority to KR1020027013896A priority patent/KR20020089482A/en
Priority to HU0301781A priority patent/HUP0301781A2/en
Priority to MXPA02010276A priority patent/MXPA02010276A/en
Priority to JP2001585697A priority patent/JP2004526662A/en
Publication of WO2001089451A2 publication Critical patent/WO2001089451A2/en
Publication of WO2001089451A3 publication Critical patent/WO2001089451A3/en
Priority to NO20025005A priority patent/NO20025005L/en
Priority to HK03104420.9A priority patent/HK1053785A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)

Abstract

The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin S in the treatment of diseases in which cathepsin S is implicated, especially treatment or prevention of autoimmune disease; treatment or prevention of a disease state caused by the formation of atherosclerotic lesions and complications arising therefrom; and diseases requiring inhibition, for therapy, of a class II MHC-restricted immune response, inhibition of an asthmatic response, inhibition of an allergic response, inhibition of immune response against a transplanted organ or tissue, or inhibition of elastase activity in atheroma, and novel compounds for use therewith.
PCT/US2001/012326 2000-04-18 2001-04-17 Protease inhibitors WO2001089451A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
KR1020027013896A KR20020089482A (en) 2000-04-18 2001-04-17 Protease inhibitors
IL15108701A IL151087A0 (en) 2000-04-18 2001-04-17 Protease inhibitors
CA002406829A CA2406829A1 (en) 2000-04-18 2001-04-17 Protease inhibitors
EP01970508A EP1278502A4 (en) 2000-04-18 2001-04-17 Protease inhibitors
BRPI0108954-4A BR0108954A (en) 2000-04-18 2001-04-17 method for inhibiting cathepsin s, 4-amino-azepan-3-one compounds as protease inhibitors and use of these compounds in the preparation of medicament for the treatment of diseases.
AU90507/01A AU9050701A (en) 2000-04-18 2001-04-17 Protease inhibitors
HU0301781A HUP0301781A2 (en) 2000-04-18 2001-04-17 4-amino-azepan-3-ones as protease inhibitors and their use
MXPA02010276A MXPA02010276A (en) 2000-04-18 2001-04-17 Protease inhibitors.
JP2001585697A JP2004526662A (en) 2000-04-18 2001-04-17 Protease inhibitor
NO20025005A NO20025005L (en) 2000-04-18 2002-10-17 protease inhibitors
HK03104420.9A HK1053785A1 (en) 2000-04-18 2003-06-19 Protease inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19849300P 2000-04-18 2000-04-18
US60/198,493 2000-04-18
US27381101P 2001-03-07 2001-03-07
US60/273,811 2001-03-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/258,053 A-371-Of-International US20030114437A1 (en) 2000-04-18 2001-04-17 Protease inhibitors
US10/797,828 Continuation US20040229863A1 (en) 2000-04-18 2004-03-10 Protease inhibitors

Publications (2)

Publication Number Publication Date
WO2001089451A2 WO2001089451A2 (en) 2001-11-29
WO2001089451A3 true WO2001089451A3 (en) 2002-04-04

Family

ID=26893840

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012326 WO2001089451A2 (en) 2000-04-18 2001-04-17 Protease inhibitors

Country Status (17)

Country Link
EP (1) EP1278502A4 (en)
JP (1) JP2004526662A (en)
KR (1) KR20020089482A (en)
CN (1) CN1431904A (en)
AR (1) AR032319A1 (en)
AU (1) AU9050701A (en)
BR (1) BR0108954A (en)
CA (1) CA2406829A1 (en)
CO (1) CO5280088A1 (en)
CZ (1) CZ20023460A3 (en)
HK (1) HK1053785A1 (en)
HU (1) HUP0301781A2 (en)
IL (1) IL151087A0 (en)
MX (1) MXPA02010276A (en)
NO (1) NO20025005L (en)
PL (1) PL366040A1 (en)
WO (1) WO2001089451A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401453A4 (en) * 2001-05-17 2005-04-06 Smithkline Beecham Corp Protease inhibitors
US20050030912A1 (en) * 2002-08-22 2005-02-10 Enikia L.L.C. Use of hybrid (HW/DSP/MCU/SW) architectures for powerline OFDM communication field
CN1708293A (en) 2002-09-24 2005-12-14 诺瓦提斯公司 S1p receptor agonist for treating demyelinate disease
AU2003273697A1 (en) * 2002-10-08 2004-05-04 Merck Frosst Canada Ltd 4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis
US7297714B2 (en) * 2003-10-21 2007-11-20 Irm Llc Inhibitors of cathepsin S
WO2007097720A2 (en) * 2006-02-21 2007-08-30 Agency For Science, Technology And Research Method and reagents for treating hepatic fibrosis and inflammation
JPWO2009054454A1 (en) * 2007-10-24 2011-03-03 国立大学法人 東京医科歯科大学 Modulator of signal transduction of Toll-like receptor containing cathepsin inhibitor as an active ingredient
EP3545953A1 (en) 2008-06-20 2019-10-02 Novartis AG Paediatric compositions for treating1 multiple sclerosis
LV15485B (en) * 2018-09-13 2020-06-20 Latvijas Organiskās Sintēzes Institūts Selenophene chromenone hydroxamic acids, their production and use in angiogenesis inhibition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518528A (en) * 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
EP0623592A1 (en) * 1993-04-29 1994-11-09 Sterling Winthrop Inc. Peptide analogs as irreversible interleukin-1beta protease inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2285A1 (en) * 1996-08-08 2002-12-25 Smithkline Beecham Corp Cysteine protease inhibitors.
TR200101869T2 (en) * 1998-12-23 2002-01-21 Smithkline Beecham Corporation Protease Inhibitors.
US7071184B2 (en) * 2000-03-21 2006-07-04 Smithkline Beecham Corporation Protease inhibitors
AU2001286983A1 (en) * 2000-09-01 2002-03-13 Smith Kline Beecham Corporation Method of treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518528A (en) * 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
EP0623592A1 (en) * 1993-04-29 1994-11-09 Sterling Winthrop Inc. Peptide analogs as irreversible interleukin-1beta protease inhibitors

Also Published As

Publication number Publication date
BR0108954A (en) 2006-05-09
CN1431904A (en) 2003-07-23
IL151087A0 (en) 2003-04-10
CO5280088A1 (en) 2003-05-30
PL366040A1 (en) 2005-01-24
WO2001089451A2 (en) 2001-11-29
KR20020089482A (en) 2002-11-29
CZ20023460A3 (en) 2004-03-17
HK1053785A1 (en) 2003-11-07
NO20025005L (en) 2002-12-06
HUP0301781A2 (en) 2003-09-29
AR032319A1 (en) 2003-11-05
EP1278502A4 (en) 2003-05-21
EP1278502A2 (en) 2003-01-29
JP2004526662A (en) 2004-09-02
AU9050701A (en) 2001-12-03
NO20025005D0 (en) 2002-10-17
CA2406829A1 (en) 2001-11-29
MXPA02010276A (en) 2003-04-25

Similar Documents

Publication Publication Date Title
EP1273298A3 (en) Ritonavir in combination with an additional HIV protease inhibitor for treating aids
WO2001089451A3 (en) Protease inhibitors
WO2002088101A3 (en) Inhibitors of bace
BRPI0308663B8 (en) use of IL-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
WO2005120476A3 (en) Novel use of peptide compounds for treating amyotrophic lateral sclerosis
WO2001070672A3 (en) Compounds and methods to treat alzheimer's disease
IL160295A0 (en) Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidines structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
EP0771565A3 (en) Angiogenesis inhibitor
WO2002002518A3 (en) Compounds to treat alzheimer's disease
WO2002002520A8 (en) Compounds to treat alzheimer's disease
WO2002069901A3 (en) Cathepsin cysteine protease inhibitors
WO2002002512A3 (en) Compounds to treat alzheimer's disease
EP1602370A3 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
WO2003011274A3 (en) Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
ATE337785T1 (en) TIOTROPIUM SALTS FOR THE TREATMENT OF INFLAMMATORY DISEASES
HK1082668A1 (en) Remedies for glomerular diseases
WO2001049295A9 (en) Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification
WO2004082706A3 (en) Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders
EP1949893A3 (en) Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
HUP0302718A2 (en) Methods and compositions for the treatment of diseases of the eye
AU2003242512A1 (en) Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease
ATE547104T1 (en) COMPOSITION CONTAINING A LUNG SURFACTANT AND SILDENAFIL FOR THE TREATMENT OF LUNG DISEASES
WO2001070233A3 (en) Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
WO2004072240A8 (en) Antiplasmin cleaving enzyme
Redwine Peritoneal blood painting: an aid in the diagnosis of endometriosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/01041/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 90507/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 151087

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 520589

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002/07872

Country of ref document: ZA

Ref document number: 200207872

Country of ref document: ZA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/010276

Country of ref document: MX

Ref document number: PV2002-3460

Country of ref document: CZ

Ref document number: 10258053

Country of ref document: US

Ref document number: 1020027013896

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2001 585697

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2406829

Country of ref document: CA

Ref document number: 018082904

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001970508

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027013896

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001970508

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-3460

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001970508

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0108954

Country of ref document: BR